Survival of Patients with Malignant Pleural Effusion: A Single Center Study

Name: Survival of Patients with Malignant Pleural Effusion: A Single Center Study
Author: Mohammad Javad Fallahi, Alireza Rezvani, Zainab Al-Saif

İsim	Survival of Patients with Malignant Pleural Effusion: A Single Center Study
Yazar	Mohammad Javad Fallahi, Alireza Rezvani, Zainab Al-Saif
Basım Tarihi:	1401
Basım Yeri	- Shiraz University of Medical Sciences, 1401.
Konu	malignant, pleural effusion, survival, Medicine, Medicine (General), R5-920
Tür	Süreli Yayın
Dil	Farsça
Dijital	Evet
Yazma	Hayır
Fiziksel Boyutlar	electronic resource
Kütüphane:	Bursa Uludağ Üniversitesi Kütüphanesi
Demirbaş Numarası	edsdoj.74ee8bfe754a35aed51313fc821cc2
Kayıt Numarası	7twhhxt6an
Lokasyon	LCC:Medicine, LCC:Medicine (General)
Tarih	1401
Örnek Metin	Malignant pleural effusion is one of the most common complications of advanced malignancies, leading to decreased quality of life and life expectancy. With the advent of new therapies, patients with malignant pleural effusion appear to be living longer than previously thought. In this cohort study,26 patients, with malignant pleural effusion at the initial diagnosis of primary cancer, who were referred to the Lung Cancer Clinic of Shahid Motahari Clinic affiliated with Shiraz University of Medical Sciences , were studied Information on age, sex, tumor type, mortality, survival rate after malignant pleural effusion, EGFR mutation (in lung cancer patients), and metastasis were evaluated. In the present study, 12 patients (46.2%) were male and 14 patients (53.8%) were female. The median survival of patients was 2 years (interquartile range 1-3 years). Five patients (19.2%) had breast cancer, 19 patients (77.1%) had lung cancer, and two patients (7.7%) had lymphoma. The highest survival after diagnosis was related to one of the lymphoma patients (five years). In lung and breast cancer patients, the median survival was two years (interquartile range 1.5, 3) and one year (interquartile range 1, 2.5), respectively. Although the present study was a small single-center study, due to the appropriate lifespan of malignant pleural effusion patients with new therapies, more comprehensive studies are needed to re-evaluate the survival of patients with malignant pleural effusion.
DOI	10.30476/smsj.2023.95854.1354
ISSN	2322-4339
İlişki	https://smsj.sums.ac.ir/article_49095_e2e960cb6296ae59c5dc73bc242a35ae.pdf; https://doaj.org/toc/2322-4339

Kaynağa git Bursa Uludağ Üniversitesi Kütüphanesi

Diğer Nüshalar

Bursa Uludağ Üniversitesi Kütüphanesi

Kaynağa git

Survival of Patients with Malignant Pleural Effusion: A Single Center Study

Yazar Mohammad Javad Fallahi, Alireza Rezvani, Zainab Al-Saif

Basım Tarihi 1401

Basım Yeri - Shiraz University of Medical Sciences, 1401.

Konu malignant, pleural effusion, survival, Medicine, Medicine (General), R5-920

Tür Süreli Yayın

Dil Farsça

Dijital Evet

Yazma Hayır

Fiziksel Boyutlar electronic resource

Kütüphane Bursa Uludağ Üniversitesi Kütüphanesi

Demirbaş Numarası edsdoj.74ee8bfe754a35aed51313fc821cc2

Kayıt Numarası 7twhhxt6an

Lokasyon LCC:Medicine, LCC:Medicine (General)

Tarih 1401

Örnek Metin Malignant pleural effusion is one of the most common complications of advanced malignancies, leading to decreased quality of life and life expectancy. With the advent of new therapies, patients with malignant pleural effusion appear to be living longer than previously thought. In this cohort study,26 patients, with malignant pleural effusion at the initial diagnosis of primary cancer, who were referred to the Lung Cancer Clinic of Shahid Motahari Clinic affiliated with Shiraz University of Medical Sciences , were studied Information on age, sex, tumor type, mortality, survival rate after malignant pleural effusion, EGFR mutation (in lung cancer patients), and metastasis were evaluated. In the present study, 12 patients (46.2%) were male and 14 patients (53.8%) were female. The median survival of patients was 2 years (interquartile range 1-3 years). Five patients (19.2%) had breast cancer, 19 patients (77.1%) had lung cancer, and two patients (7.7%) had lymphoma. The highest survival after diagnosis was related to one of the lymphoma patients (five years). In lung and breast cancer patients, the median survival was two years (interquartile range 1.5, 3) and one year (interquartile range 1, 2.5), respectively. Although the present study was a small single-center study, due to the appropriate lifespan of malignant pleural effusion patients with new therapies, more comprehensive studies are needed to re-evaluate the survival of patients with malignant pleural effusion.

DOI 10.30476/smsj.2023.95854.1354

ISSN 2322-4339

İlişki https://smsj.sums.ac.ir/article_49095_e2e960cb6296ae59c5dc73bc242a35ae.pdf; https://doaj.org/toc/2322-4339

Survival of Patients with Malignant Pleural Effusion: A Single Center Study

Diğer Nüshalar